Skip to content

The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality

The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00487162
Enrollment
56
Registered
2007-06-15
Start date
2007-06-30
Completion date
2009-01-31
Last updated
2016-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperglycemia

Keywords

glycemic control, diabetes, obesity, comorbidities

Brief summary

Surgery induces a stress effect on the body partially through a catabolic energy state. In turn, glucose levels may rise to levels which have been associated with major morbidity (Golden, 1999) and mortality (Ouattara, 2005). An increasing body of evidence suggests that intensive insulin therapy for tight control of blood glucose levels in certain surgical and critical care patient populations may improve mortality and selected morbidity outcomes when compared to those patients receiving conventional insulin therapy and blood glucose management. More specifically, poor intra-operative blood glucose control is associated with worse outcome after cardiac surgery. Intensive insulin therapy with tight blood glucose control in surgical patients while in the ICU may reduce morbidity and mortality. Such outcome improvements would clearly provide benefits to patients, providers and payers. To date, there is scant research examining whether intensive insulin therapy for tight control of blood glucose in the perioperative period can alter outcomes for the non cardiac surgery population. The purpose of this study is to determine whether intensive insulin therapy for tight control of blood glucose in the perioperative period in non cardiac major surgery patients is associated with altered morbidity and mortality rates.

Detailed description

Intensive insulin therapy to control blood glucose levels reduces morbidity and mortality in intensive care unit patients and in cardiac surgical patients but its role in patients undergoing non-emergent non-cardiac surgery is unknown. Benefits of glucose control may result from prevention of immune system dysfunction, reduction in systemic inflammation, and protection of endothelium and mitochondrial structure and function, all of which are known to be altered by high stress states such as that induced by surgical procedures. In a prospective, randomized, controlled study of adult patients admitted to our operating suite for non-emergent non-cardiac surgery, we propose to correlate in-hospital morbidity and mortality with blood glucose levels of patients who are expected to have moderate to high levels of physiologic stress as a result of their pre-existing medical conditions or as a result of the proposed surgical procedure. Specifically, patients who are deemed to be American Society of Anesthesiologists Risk Classification 1-3 or higher, or patients undergoing intermediate and high risk procedures shall be considered to have moderate to high physiologic stress. Determination of intermediate / high risk procedures shall be according to the American College of Cardiology / American Heart Association 2002 Guidelines for Perioperative Cardiovascular Evaluation for Noncardiac Surgery as outlined in Table 1. Table 1. Cardiac Event Risk Stratification for Noncardiac Surgical Procedures High (Reported cardiac risk often \>5%) * Emergent major operations, particularly in the elderly * Aortic and other major vascular surgery * Peripheral vascular surgery * Anticipated prolonged surgical procedures associated with large fluid shifts and/or blood loss Combined incidence of cardiac death and nonfatal myocardial infarction. Further preoperative cardiac testing is not generally required. Intermediate (Reported cardiac risk generally \<5%) * Intraperitoneal and intrathoracic surgery * Carotid endarterectomy surgery * Head and neck surgery * Orthopedic surgery * Prostate surgery Low (Reported cardiac risk generally \<1%): * Endoscopic procedures * Superficial procedures * Cataract surgery * Breast surgery Prior to entering the operating suite for surgery, patients will be randomly assigned to receive either intensive insulin treatment or conventional insulin treatment. Treatment assignment will be performed using sealed envelopes, and patients stratified according to Table 2. TABLE 2. Baseline Characteristics of Patients. Variable Intention to Treat Group P Value Male sex (%) Age (Years) Type of Surgery * Intracranial (%) * Head & Neck (%) * Thoracic (%) * Vascular (%) * Gastrointestinal (%) * Urologic (%) * Orthopedic (%) * Gynecologic (%) * Myocutaneous (%) History of Cancer (%) History of Organ Failure before Surgery (%) Organ Failure After Surgery (%) History of Diabetes (%) * Treated with insulin * Treated with oral diabetic agent, diet or both Inclusion criteria: * Patients scheduled for non emergent surgery under either general or regional anesthesia deemed to have moderate to high physiologic stress * Male and female subjects over the age of 18 with or without a diagnosis of diabetes mellitus * Patients must be able to provide informed consent Exclusion criteria: * Cognitively impaired * Non-English or Spanish speaking with no relative present who is fluent in reading and comprehending English or Spanish. * Female patients of child bearing age who have a positive pregnancy test on admission. In all patients, whole blood hemoglobin A1C and glucose levels will be drawn prior to induction of anesthesia. Additional whole blood glucose levels will be drawn at the time of induction of anesthesia, at skin incision, hourly throughout the operation, at emergence from anesthesia, every hour up to three hours after the completion of surgery, and then once per day until the patient is discharged from the hospital. In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R \[Novo Nordisk\]) in 50mL of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg/dL and will be adjusted to maintain the blood glucose level between 80 and 110 mg/dL. Adjustments will be made according to the University Hospital's ICU Adult Insulin Infusion Protocol. When the blood glucose level falls below 80 mg/dL, the insulin infusion will be tapered and discontinued. For patients going to the ICU after surgery, insulin infusions will be continued according to the University Hospital's ICU Adult Insulin Infusion Protocol under the direction of the ICU staff. For patients not being to the ICU after surgery, insulin infusions will be tapered to off after the final hourly blood glucose determination at three hours after the completion of surgery. The University Hospital's Blood Glucose Management Order Set for Medical and Surgical Patients will then be adopted for continued glucose management. In the conventional treatment group, continuous insulin infusion will be started when the blood glucose level exceeds 200 mg/dL and will be adjusted to maintain the blood glucose level between 180 and 200 mg/dL. Adjustments will be made according to a modified ICU Adult Insulin Infusion Protocol. When the blood glucose level falls below 180mg/dL, the insulin infusion will be tapered and discontinued. For patients transferred to an ICU after surgery, insulin infusions will be continued according to the University Hospital's ICU Adult Insulin Infusion Protocol under the direction of the ICU staff. For patients not being transferred to an ICU after surgery, insulin infusions will be tapered to off after the final hourly blood glucose determination at three hours after the completion of surgery. The University Hospital's Blood Glucose Management Order Set for Medical and Surgical Patients will then be adopted for continued glucose management. How will the study be analyzed? At baseline, data on demographic and clinical characteristics of the patients (see Table 1) will be obtained. Blood will be systematically sampled and whole blood glucose levels determined as described above. All blood glucose values will be tabulated from baseline through end of study. A research associate blinded to the treatment groups will determine morbidity and mortality by reviewing the patient's medical record upon discharge from the hospital and recording the occurrence of morbidity and mortality by the following criteria: 1. Post-operative surgical wound infection - a clinical condition requiring antibiotic treatment beyond the UH Surgical Infection Prevention (SIP) protocol and / or subsequent wound drainage / debridement 2. Systemic infection - presence of bacteremia or prolonged (i.e. greater than 10 days) use of antibiotics 3. Myocardial Injury - postoperative EKG changes that reveal new Q waves or S-T segment elevations greater than 1mm in any lead(s) or serum troponin levels that exceed…. 4. Malignant arrhythmia - asystole, ventricular tachycardia or fibrillation requiring cardiopulmonary resuscitation, antiarrhythmia therapy, or defibrillator implantation 5. Respiratory Injury - mechanical ventilation for more than 48 hours, reintubation, or planned tracheostomy 6. Neurological Injury - focal brain injury with permanent functional deficit, irreversible encephalopathy 7. Renal Injury - a level of serum creatinine twice that present on admission to the hospital or acute renal failure requiring dialysis 8. Hepatic Injury - bilirubin level of \>3mg per deciliter 9. Venous Thromboembolism - deposition of thrombus in peripheral or central veins as determined by Doppler ultrasonography, angiography or computed tomography.

Interventions

intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl

Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl

Sponsors

University of Medicine and Dentistry of New Jersey
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

* Patients scheduled for non emergent surgery under either general or regional anesthesia deemed to have moderate to high physiologic stress * Male and female subjects over the age of 18 with or without a diagnosis of diabetes mellitus * Patients must be able to provide informed consent

Exclusion criteria

* Cognitively impaired * Non-English or Spanish speaking with no relative present who is fluent in reading and comprehending English or Spanish. * Female patients of child bearing age who have a positive pregnancy test on admission.

Design outcomes

Primary

MeasureTime frame
Wound Infection7-10 days post op

Secondary

MeasureTime frame
Hemodynamic Instability0-48 hours post op

Countries

United States

Participant flow

Recruitment details

enrollment period 6/07-3/09. potential subjects were recruited from the pre-operative admission unit and were screened if there ages were 18-90,undergoing general anesthesia for surgical procedures greater than 2 hours.

Pre-assignment details

Subjects were randomized to a specific study arm based on a computer generated randomization table. 49 participants are included in the baseline characteristic module because although 56 signed consent, some subjects withdrew the consent prior to study procedures and several withdrawn by attending anesthesiologist.

Participants by arm

ArmCount
Conventional Glycemic Control
Subjects randomized to this study arm had their glucose levels monitored hourly and if the result was greater than 200 mg/dL their anesthesia care provider was notified. The subject was treated as to their care provider discretion.
28
Intensive Glycemic Control
In this treatment group, continuous insulin infusion (50 IU of Novolin R \[Novo Nordisk\]) in 50mL of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg/dL and will be adjusted to maintain the blood glucose level between 80 and 110 mg/dL.
21
Total49

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event01
Overall StudyPhysician Decision01
Overall StudyWithdrawal by Subject23

Baseline characteristics

CharacteristicIntensive Glycemic ControlConventional Glycemic ControlTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
1 Participants3 Participants4 Participants
Age, Categorical
Between 18 and 65 years
20 Participants25 Participants45 Participants
Sex: Female, Male
Female
13 Participants12 Participants25 Participants
Sex: Female, Male
Male
8 Participants16 Participants24 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 281 / 21
serious
Total, serious adverse events
0 / 280 / 21

Outcome results

Primary

Wound Infection

Time frame: 7-10 days post op

Population: no analysis was done as the study was terminated due to patient safety concerns

Secondary

Hemodynamic Instability

Time frame: 0-48 hours post op

Population: no analysis was done as the study was terminated due to patient safety concerns

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026